Articles tagged with: Revlimid
As the myeloma community continues to investigate whether stem cell transplantation or novel agents is the best way to treat newly diagnosed myeloma patients, recent results from a Phase 3 clinical trial indicate that stem cell transplantation may lead to longer disease-free survival.
The results from this study show that more multiple myeloma patients who received a stem cell transplant were alive and disease-free after 24 months compared to patients treated with Revlimid in combination with conventional chemotherapy.
The transplanted patients, however, also experienced more severe side effects compared to …
Results of a Phase 2 clinical trial show that elotuzumab in combination with Revlimid and low-dose dexamethasone is safe and effective in relapsed/refractory multiple myeloma patients.
“Elotuzumab in combination with Revlimid and low-dose dexamethasone has a very high response rate,” said Dr. Philippe Moreau from the University Hospital in Nantes, France, when he presented the findings at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday.
“[The combination] seems to be superior to Revlimid plus high-dose dexamethasone,” he added.
In a summary talk about potential …
Monday was the fourth day of the American Society of Clinical Oncology (ASCO 2011) annual meeting in Chicago. Although the meeting concluded yesterday, Monday was the last day of the meeting that contained any myeloma-relevant material.
The morning started with a session recapping highlights of the meeting from Sunday. Dr. Ivan Borello from the Johns Hopkins University School of Medicine was invited to give a 15-minute presentation recapping the myeloma highlights (see Part 1 and Part 2 of The Beacon’s Day Three update for more information).
The rest …
Three myeloma experts yesterday presented additional clinical trial data on the possible link between Revlimid and secondary cancer in multiple myeloma patients. All three experts concluded that Revlimid’s benefit as a myeloma treatment outweighs its risks.
The presentations were made at a session of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
In a summary talk reviewing the three presentations, Dr. Ola Landgren from the U.S. National Cancer Institute noted that the risk of developing a secondary cancer following Revlimid (lenalidomide) therapy was significantly lower than …
Yesterday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting in Chicago, and it was especially packed with presentations related to multiple myeloma.
There was a morning session where a total of eight research abstracts were presented and discussed. Then, late in the afternoon, there was an education session focused on multiple myeloma, with several different presentations.
The presentations during the morning session were on three different topics: Revlimid (lenalidomide) and its potential link to secondary cancer; myeloma bone disease; and new drugs being developed …